Shanmugam Muthusamy's Form 4/A amendment
AmendedAni Pharmaceuticals Inc (ANIP) · filed Nov 20, 2023
- Accession no.
- 0001870913-23-000016
- Filed
- Nov 20, 2023
- Trade date
- Nov 14-16, 2023
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Nov 16, 2023
This filing lists 3 non-derivative transactions. Open-market sales total $1.96M. It was filed 6 days after the trade.
This amendment replaces 0001870913-23-000013 (filed Nov 16, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shanmugam MuthusamyCIK 0001870913 | Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2023 | Common Stock | SSaleDisposed | −22,905 | $53.17F2 | −$1,217,858.85 | 1,009,715 | Indirect | |
| Nov 15, 2023 | Common Stock | SSaleDisposed | −7,647 | $53.64F4 | −$410,185.08 | 1,002,068 | Indirect | |
| Nov 16, 2023 | Common Stock | SSaleDisposed | −6,448 | $51.66F5 | −$333,103.68 | 995,620 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.95 to $54.07, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.96 to $54.24, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.14 to $52.70, inclusive
Referenced by the price of 1 transaction in Table I.
Remarks
This amendment is being filed to address an administrative error in reporting the number of shares sold in a transaction on November 14, 2023.